医学沟通顾问（商丘）

上海艾力斯医药科技股份有限公司

Chinese biopharmaceutical company based in Shanghai and listed on the Shanghai STAR Market under code 688578, focused on small molecule targeted therapies for cancer. Its lead product furmonertinib, a third-generation EGFR tyrosine kinase inhibitor marketed in China as Ivesa, is approved for non-small cell lung cancer in both later-line and first-line settings, and the company runs its own research, manufacturing and commercial operations with further oncology candidates in development.